Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice

Table 8 Prevalence of psychotropic drugs at time of discharge (1996–2004 versus 2008–2012)

	Rates of psychotropic drugs¹
	2008–2012	1996–2004
	N = 87	N = 142	Fisher’s exact (p value)
antipsychotics	46	37.3	0.2139
antidepressants	67.8	56.3	0.0953
hypnotics / sedatives	24,1	24,6	10.000
mood stabilizers	9.2	24.6	0.0048
valproic acid	3.4	2.8
carbamazepine	3.4	20.4
lamotrigine	2.3	0
naltrexone	35.6	6.3	< 0.0001
overall	94	71.8	< 0.0001
	Rates of antipsychotics²
	2008–2012	1996–2004
	N = 40	N = 53	Fisher’s exact (p value)
low-potency antipsychotics	42.5	83	< 0.0001
high-potency antipsychotics	5	17	0.1073
second generation antipsychotics	60	43.3	0.1438
	Rates of antidepressants³
	2008–2012	1996–2004
	N = 59	N = 80	Fisher’s exact (p value)
tri−/tetracyclic antidepressants	13.6	53.8	< 0.0001
SSRI	55.9	56.3	0.9702
MAO inhibitors	0	11.3
atypical antidepressants	42.4	37.5	0.6013

¹Rates in %; N number of patients of the cohort. Bonferroni correction (p < 0.008). Significant p-values are highlighted in bold
²Rates in %; reference is number of patients receiving antipsychotics (N). Bonferroni correction (p < 0.016). Significant p-values are highlighted in bold
³Rates in %; reference is number of patients receiving antidepressants (N). Bonferroni correction (p < 0.0125). Significant p-values are highlighted in bold

ISSN: 1471-244X